Endothelin A and B receptor antagonist bosentan reduces postischemic myocardial injury in the rat: critical timing of administration

By Xia Zhengyuan   Kuo Kuo-Hsing   McNeill John H   Ansley David M  

Canadian Journal of Physiology and Pharmacology, Vol. 83, Iss. 3, 2005-03 ,pp. : 259-266

NRC Research Press

Access to resources Recommend Favorite

Beneficial effects of the endothelin receptor antagonist bosentan on myocardial and endothelial injury following ischaemia/reperfusion in the rat

By Xing-San L.   Qing-Dong W.   John P.  

European Journal of Pharmacology, Vol. 283, Iss. 1, 1995-09 ,pp. : 161-168

Elsevier

Access to resources Recommend Favorite

Pharmacological characterization of YM598, an orally active and highly potent selective endothelin ET A receptor antagonist

By Yuyama H.   Sanagi M.   Koakutsu A.   Mori M.   Fujimori A.   Harada H.   Sudoh K.   Miyata K.  

European Journal of Pharmacology, Vol. 478, Iss. 1, 2003-09 ,pp. : 61-71

Elsevier

Access to resources Recommend Favorite

ZD1611, an Orally Active Endothelin-A Receptor Antagonist, Prevents Chronic Hypoxia-induced Pulmonary Hypertension in the Rat

By Bialecki R.A.   Fisher C.S.   Abbott B.M.   Barthlow H.G.   Caccese R.G.   Stow R.B.   Rumsey J.   Rumsey W.  

Pulmonary Pharmacology & Therapeutics, Vol. 12, Iss. 5, 1999-10 ,pp. : 303-312

Academic Press

Access to resources Recommend Favorite

Bosentan: a dual endothelin receptor antagonist

By Roux Sébastien   Rubin Lewis J  

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 7, 2002-07 ,pp. : 991-1002

Informa Healthcare

Access to resources Recommend Favorite